Skip to main content
Erschienen in: Reproductive Medicine and Biology 2/2016

08.08.2015 | Original Article

An evaluation of the Gifu Model in a trial for a new regional oncofertility network in Japan, focusing on its necessity and effects

verfasst von: Tatsuro Furui, Motoki Takenaka, Hiroshi Makino, Keiko Terazawa, Akio Yamamoto, Ken-ichiro Morishige

Erschienen in: Reproductive Medicine and Biology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We evaluated our 2-year experience of the regional oncofertility network in Gifu Prefecture (GPOFS) in order to establish a more sophisticated regional oncofertility networking model in Japan.

Methods

Questionnaires were distributed twice in January 2013 to 57 departments in 35 hospitals that provide cancer treatment in Gifu Prefecture, before the establishment of the regional oncofertility network. The number and type of disease of the referred adolescent and young adult (AYA) cancer patients who visited the oncofertility clinic in Gifu University Hospital via the GPOFS were analyzed.

Results

The majority of regional oncologists are aware of the need to provide information about oncofertility to their patients, but they cannot provide sufficient information due to their lack of knowledge about reproductive medicine. Eighty-one AYA patients were referred to our clinic for oncofertility counseling in the first 2 years after the establishment of the GPOFS.

Conclusions

The GPOFS as the first regional oncofertility network in Japan has just started and may be working to help both AYA cancer patients and their oncologists. The nationwide establishment of the regional oncofertility network model could help both AYA cancer patients and oncologists.
Literatur
1.
Zurück zum Zitat Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28:4831–41.CrossRefPubMed Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28:4831–41.CrossRefPubMed
3.
Zurück zum Zitat Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril. 2010;94:1652–6.CrossRefPubMed Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril. 2010;94:1652–6.CrossRefPubMed
4.
Zurück zum Zitat Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau JE. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertil Steril. 2012;97:671–6.CrossRefPubMedPubMedCentral Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau JE. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertil Steril. 2012;97:671–6.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500–10.CrossRefPubMed Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500–10.CrossRefPubMed
6.
Zurück zum Zitat Suzuki N. Ovarian tissue cryopreservation in young cancer patients for fertility preservation. Reprod Med Biol. 2015;14:1–4.CrossRef Suzuki N. Ovarian tissue cryopreservation in young cancer patients for fertility preservation. Reprod Med Biol. 2015;14:1–4.CrossRef
7.
Zurück zum Zitat Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod. 2015;30:608–15.CrossRefPubMed Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod. 2015;30:608–15.CrossRefPubMed
8.
Zurück zum Zitat Kim J, Deal AM, Balthazar U, Kondapalli LA, Gracia C, Mersereau JE. Fertility preservation consultation for women with cancer: are we helping patients make high-quality decisions? Reprod Biomed Online. 2013;27:96–103.CrossRefPubMed Kim J, Deal AM, Balthazar U, Kondapalli LA, Gracia C, Mersereau JE. Fertility preservation consultation for women with cancer: are we helping patients make high-quality decisions? Reprod Biomed Online. 2013;27:96–103.CrossRefPubMed
9.
Zurück zum Zitat Nishijima C, Suzuki N. [Fertility Problems in Oncofertility Treatment—Including ASCO Guidelines]. Gan To Kagaku Ryoho. 2015;42:283–8 (Article in Japanese).PubMed Nishijima C, Suzuki N. [Fertility Problems in Oncofertility Treatment—Including ASCO Guidelines]. Gan To Kagaku Ryoho. 2015;42:283–8 (Article in Japanese).PubMed
10.
Zurück zum Zitat Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M. Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet. 2011;283:651–6.CrossRefPubMed Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M. Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet. 2011;283:651–6.CrossRefPubMed
11.
Zurück zum Zitat Waimey KE, Duncan FE, Su HI, Smith K, Wallach H, Jona K, et al. Future directions in oncofertility and fertility preservation: a report from the 2011 oncofertility consortium conference. J Adolesc Young Adult Oncol. 2013;2:25–30.CrossRefPubMedPubMedCentral Waimey KE, Duncan FE, Su HI, Smith K, Wallach H, Jona K, et al. Future directions in oncofertility and fertility preservation: a report from the 2011 oncofertility consortium conference. J Adolesc Young Adult Oncol. 2013;2:25–30.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011;284:427–35.CrossRef von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011;284:427–35.CrossRef
Metadaten
Titel
An evaluation of the Gifu Model in a trial for a new regional oncofertility network in Japan, focusing on its necessity and effects
verfasst von
Tatsuro Furui
Motoki Takenaka
Hiroshi Makino
Keiko Terazawa
Akio Yamamoto
Ken-ichiro Morishige
Publikationsdatum
08.08.2015
Verlag
Springer Japan
Erschienen in
Reproductive Medicine and Biology / Ausgabe 2/2016
Print ISSN: 1445-5781
Elektronische ISSN: 1447-0578
DOI
https://doi.org/10.1007/s12522-015-0219-3

Weitere Artikel der Ausgabe 2/2016

Reproductive Medicine and Biology 2/2016 Zur Ausgabe

Announcement

Announcement

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.